Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“DC Approval!! US FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- Breast Cancer previously treated with endocrine and chemotherapy for unresectable, metastatic disease. ”
